Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medicenna Therapeutics Corp ( (TSE:MDNA) ) has issued an announcement.
Medicenna Therapeutics Corp announced updated clinical trial results for MDNA11 at the ESMO-IO Congress 2025, highlighting its durable anti-tumor activity in advanced solid tumors, particularly in immune checkpoint-resistant cancers. The trial demonstrated promising objective response rates and disease control rates in various cancer types, indicating MDNA11’s potential efficacy in earlier lines of treatment. The results suggest meaningful therapeutic potential, with a manageable safety profile, reinforcing MDNA11’s positioning as a promising candidate in the oncology market.
The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Spark’s Take on TSE:MDNA Stock
According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.
Medicenna Therapeutics Corp. receives a moderate overall score, reflecting its financial challenges and reliance on financing. However, positive results from clinical trials and promising preclinical data provide notable upside potential. Technical indicators are neutral, offering a balanced view of near-term stock performance. Valuation highlights the speculative nature typical of biotech stocks, while recent corporate events significantly bolster future growth prospects.
To see Spark’s full report on TSE:MDNA stock, click here.
More about Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a clinical-stage immunotherapy company focused on developing Superkines targeting cancer and autoimmune diseases. The company is engaged in evaluating MDNA11, a long-acting interleukin-2 super-agonist, as a monotherapy or in combination with Merck’s anti-PD-1 therapy, KEYTRUDA, for treating advanced solid tumors.
Average Trading Volume: 84,943
Technical Sentiment Signal: Buy
Current Market Cap: C$112.7M
For detailed information about MDNA stock, go to TipRanks’ Stock Analysis page.